Juno Therapeutics Inc (NASDAQ:JUNO) shares reached a new 52-week low during trading on Wednesday after Maxim Group lowered their price target on the stock from $50.00 to $34.00. Maxim Group currently has a buy rating on the stock. Juno Therapeutics traded as low as $22.15 and last traded at $21.95, with a volume of 13,273,838 shares trading hands. The stock had previously closed at $29.88.

A number of other research analysts have also issued reports on the stock. FBR & Co set a $61.00 price target on shares of Juno Therapeutics and gave the stock a “buy” rating in a research note on Friday, August 5th. Standpoint Research began coverage on shares of Juno Therapeutics in a research note on Thursday, August 25th. They set a “buy” rating and a $47.00 price target on the stock. BTIG Research upgraded shares of Juno Therapeutics from a “sell” rating to a “neutral” rating in a research note on Thursday, November 3rd. Zacks Investment Research lowered shares of Juno Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 5th. Finally, Vetr lowered shares of Juno Therapeutics from a “strong-buy” rating to a “buy” rating and set a $38.02 price target on the stock. in a research note on Tuesday, August 16th. Five research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. Juno Therapeutics presently has an average rating of “Buy” and a consensus price target of $43.13.

In related news, EVP Robert Azelby sold 12,921 shares of the company’s stock in a transaction that occurred on Thursday, November 10th. The shares were sold at an average price of $24.14, for a total transaction of $311,912.94. Following the transaction, the executive vice president now owns 48,640 shares of the company’s stock, valued at $1,174,169.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Hans Edgar Bishop sold 84,035 shares of the company’s stock in a transaction that occurred on Wednesday, September 21st. The shares were sold at an average price of $30.28, for a total transaction of $2,544,579.80. Following the transaction, the chief executive officer now directly owns 2,518,537 shares in the company, valued at approximately $76,261,300.36. The disclosure for this sale can be found here.

Institutional investors have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD increased its position in shares of Juno Therapeutics by 0.4% in the third quarter. Price T Rowe Associates Inc. MD now owns 23,698 shares of the biopharmaceutical company’s stock valued at $711,000 after buying an additional 98 shares during the last quarter. Boyer & Corporon Wealth Management LLC increased its position in shares of Juno Therapeutics by 0.9% in the second quarter. Boyer & Corporon Wealth Management LLC now owns 12,579 shares of the biopharmaceutical company’s stock valued at $484,000 after buying an additional 115 shares during the last quarter. Profund Advisors LLC increased its position in shares of Juno Therapeutics by 0.4% in the second quarter. Profund Advisors LLC now owns 39,877 shares of the biopharmaceutical company’s stock valued at $1,533,000 after buying an additional 148 shares during the last quarter. Legal & General Group Plc increased its position in shares of Juno Therapeutics by 5.9% in the second quarter. Legal & General Group Plc now owns 5,470 shares of the biopharmaceutical company’s stock valued at $210,000 after buying an additional 306 shares during the last quarter. Finally, BlackRock Investment Management LLC increased its position in shares of Juno Therapeutics by 1.3% in the third quarter. BlackRock Investment Management LLC now owns 25,635 shares of the biopharmaceutical company’s stock valued at $769,000 after buying an additional 320 shares during the last quarter.

The stock’s market cap is $2.31 billion. The stock’s 50-day moving average is $27.75 and its 200 day moving average is $33.02.

Juno Therapeutics (NASDAQ:JUNO) last issued its quarterly earnings data on Wednesday, November 9th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by $0.05. The company had revenue of $20.80 million for the quarter, compared to analysts’ expectations of $10.98 million. The firm’s revenue was up 1200.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.26) EPS. On average, analysts forecast that Juno Therapeutics Inc will post ($2.54) EPS for the current fiscal year.

WARNING: This piece was originally published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this piece on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2016/11/25/juno-therapeutics-inc-juno-sets-new-52-week-low-following-analyst-downgrade.html.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

5 Day Chart for NASDAQ:JUNO

Receive News & Stock Ratings for Juno Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc and related stocks with our FREE daily email newsletter.